Pulmozyme® (dornase alfa) Co-pay and Financial Support

Genentech Access Solutions is committed to helping people understand how to get Pulmozyme


If you would like help paying for Pulmozyme, there may be options to help you get the medicine you need. Find out which assistance option might be right for you by using our Patient Assistance Tool.


At Genentech Access Solutions, we are committed to making sure you get your prescribed medicine. Over the past 20 years, we have helped over 1.5 million patients get the medicines they need.

If you are eligible, there may be options to help you pay for Pulmozyme*:

  • Genentech co-pay cards
  • Genentech offers the Pulmozyme Co-pay Card that may help eligible commercially insured patients with the out-of-pocket costs of Pulmozyme.
  • Referrals to independent co-pay assistance foundations
  • Independent co-pay assistance foundations help patients with public health insurance or commercial health insurance.
  • The Genentech® Access to Care Foundation, or GATCF
  • GATCF helps people who don't have health insurance. It also helps people who have health insurance but have trouble paying for Pulmozyme. If you qualify for GATCF, you could receive Pulmozyme free of charge.

To get started, complete a form called the PAN.

To find out which of our assistance options is right for you, visit Genentech-Access.com/Pulmozyme/patients or call (800) 690-3023.

  • *Patients must meet certain criteria.
  • †In order to be eligible for the Pulmozyme Co-pay Card, you must confirm that you meet the eligibility criteria and agree to the rules set forth in the terms and conditions for the program. Please visit www.pulmozymecopaycard.com for the full list of terms and conditions.
  • ‡Independent co-pay assistance foundations have their own rules for eligibility. We cannot guarantee a foundation will help you. We only can refer you to a foundation that supports your disease state. We do not endorse or show financial preference for any particular foundation. The foundations we refer you to are not the only ones that might be able to help you.

Continue reading for Pulmozyme resources ›

Indication and Usage

Pulmozyme (dornase alfa) is indicated for daily administration along with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function.

In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.

Important Safety Information

Pulmozyme should not be used in patients who are allergic to any of its ingredients.

Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion, and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.

Pediatric Use

The safety and effectiveness of Pulmozyme have been established in patients 5 years of age and older. While clinical trial data are limited in patients younger than 5 years of age, the use of Pulmozyme should be considered for pediatric CF patients who may experience potential benefit in lung function or who may be at risk of respiratory tract infection.

The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to <5 years (younger group) and 33 aged 5 years to <10 years (older group). The PARI BABY™ reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. Overall, the kind of side effects observed in children was similar to those seen in larger trials in older patients.

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

For additional Important Safety Information, please click here for the Pulmozyme full Prescribing Information. If you have questions, please discuss them with your CF Care Team.